This frequency was close to two multicenter studies from eastern and north China ovarian cancer patients by NGS (Shi et al., 2017; Wu et al., 2017) 16.7% (13.1% in BRCA1 and 3.9% in BRCA2) and 28.4% (20.8% in BRCA1 and 7.6% in BRCA2), respectively. This evidence concerns the gene BRCA1 and ovarian carcinoma.